Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Immune-Mediated Dermatology Reactions IMFINZI and IMJUDO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia ...

WILMINGTON, Del., June 01, 2025--(BUSINESS WIRE)--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI ® (durvalumab) in combination ...

rash, pyrexia, diarrhea, vomiting and abdominal pain. “Today’s approval for Imfinzi represents a paradigm shift, bringing the first perioperative immunotherapy to patients in the US with ...

MISSISSAUGA, ON, April 10, 2025 /CNW/ - Health Canada has granted a Notice of Compliance (NOC) for IMFINZI® (durvalumab), as monotherapy, for the treatment of adult patients with limited-stage ...

Findings of the phase 2 INFINITY trial (NCT04817826) indicate that a chemotherapy-free regimen of tremelimumab (Imjudo) plus durvalumab (Imfinzi; T300/D) exhibited promising antitumor activity in ...

The US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab ... increased alkaline phosphate, rash, pyrexia, diarrhea, vomiting, and abdominal pain.

Immune-Mediated Dermatology Reactions IMFINZI can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic ...